Long Focus Capital Management LLC Buys New Stake in Bicycle Therapeutics plc (NASDAQ:BCYC)

Long Focus Capital Management LLC bought a new stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 543,092 shares of the company's stock, valued at approximately $7,603,000. Long Focus Capital Management LLC owned approximately 0.79% of Bicycle Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Barclays PLC increased its holdings in Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after purchasing an additional 2,345 shares during the period. Avior Wealth Management LLC purchased a new stake in shares of Bicycle Therapeutics during the fourth quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. raised its holdings in Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after acquiring an additional 2,191 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after purchasing an additional 1,782 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Bicycle Therapeutics by 35.7% in the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock valued at $457,000 after purchasing an additional 5,310 shares in the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Stock Down 2.0 %

NASDAQ BCYC traded down $0.17 during trading hours on Monday, hitting $8.25. 37,891 shares of the stock were exchanged, compared to its average volume of 344,566. Bicycle Therapeutics plc has a 12-month low of $6.10 and a 12-month high of $28.67. The stock has a 50-day moving average of $9.00 and a 200 day moving average of $14.94. The company has a market cap of $571.05 million, a price-to-earnings ratio of -2.51 and a beta of 1.40.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.47 million. During the same period in the prior year, the company posted ($1.16) EPS. The business's revenue for the quarter was down 30.2% on a year-over-year basis. On average, equities research analysts expect that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Stephens reissued an "equal weight" rating and issued a $15.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.14.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.